
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL Inc has demonstrated a significant stock appreciation of nearly 90% over the past month, highlighting increasing investor confidence driven by promising data from the PATHFINDER 2 trial. The company's multi-cancer early detection blood test addresses a substantial total addressable market (TAM) in both the US and UK, with projections indicating potential opportunities of approximately $3.7 billion by 2026 and growing to $4.0 billion by 2035. Additionally, GRAIL's strategic partnerships and improved outlook following the recent ESMO data readout contribute to a positive perspective on future growth, despite existing uncertainties regarding regulatory approvals and Medicare reimbursement.
Bears say
GRAIL Inc. has consistently reported significant net losses since its inception and expects these losses to persist as it continues clinical studies and seeks necessary regulatory approvals. The company faces several risks, including potential delays in government reimbursement processes and increasing competition from established diagnostics firms, which may hinder its market adoption of the multi-cancer early detection test. Additionally, high selling, general, and administrative expenses could further strain GRAIL's financial resources, particularly if the company fails to secure additional financing for commercialization efforts.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares